USC Pharmacy Alumni π | Full-Time Investor π
My posts reflect my personal investment views, not investment recommendations. Always do your own due diligence.
Important to remember, these are sicker patients than Paradigm so this is setting up for higher probability successful primary and secondary endpoints. Also this is 20% of the size of paradigm DurAvr arm so itβs not a tiny n, obviously. $avr
Potential blockbuster M&A in cybersecurity.
Bloomberg reporting that $CRWD is in talks to buy $ZS.
Would give the endpoint titan (& so much more now) a lot more muscle in network.
Would give CrowdStrike a far more complete product suite to match $PANW's breadth too.
While Zscaler may be struggling a bit to expand to other categories... they are world-class in network. CrowdStrike is world-class in a lot of other things.
Seems like a good fit.
$NVDA News flow continue to pile on. True or false, every headline creates another round of debate, fear, and uncertainty. It's been quite painful for the market and investors since Jensen entered the spotlight.
You weren't Warren Buffett 2.0 on the way up.
You are not an idiot today.
We are both somewhere firmly in between.
And as long as we're acting responsibly, that's entirely fine. We will be fine.
There will be brighter days. Great companies will not get cheaper forever.